FY2024 Earnings Estimate for MaxCyte Issued By William Blair

MaxCyte, Inc. (NASDAQ:MXCT - Free Report) - William Blair raised their FY2024 earnings per share (EPS) estimates for shares of MaxCyte in a note issued to investors on Thursday, November 7th. William Blair analyst M. Larew now expects that the company will post earnings per share of ($0.43) for the year, up from their prior forecast of ($0.47). The consensus estimate for MaxCyte's current full-year earnings is ($0.43) per share. William Blair also issued estimates for MaxCyte's Q4 2024 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.10) EPS and FY2025 earnings at ($0.46) EPS.

MaxCyte Stock Up 5.9 %

MXCT traded up $0.20 during trading on Monday, reaching $3.58. The company's stock had a trading volume of 654,041 shares, compared to its average volume of 514,586. The firm has a fifty day simple moving average of $3.83 and a two-hundred day simple moving average of $4.18. The company has a market cap of $377.63 million, a price-to-earnings ratio of -10.38 and a beta of 1.40. MaxCyte has a 1 year low of $3.23 and a 1 year high of $5.55.

MaxCyte (NASDAQ:MXCT - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.02. The firm had revenue of $8.16 million during the quarter, compared to analysts' expectations of $7.50 million. MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%. During the same period in the previous year, the business earned ($0.11) earnings per share.

Insider Buying and Selling at MaxCyte

In other news, Director Stanley C. Erck sold 29,767 shares of the stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $3.97, for a total value of $118,174.99. Following the completion of the sale, the director now owns 269,118 shares of the company's stock, valued at $1,068,398.46. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, Director Stanley C. Erck sold 21,607 shares of MaxCyte stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $3.71, for a total value of $80,161.97. Following the completion of the transaction, the director now owns 269,118 shares in the company, valued at approximately $998,427.78. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Stanley C. Erck sold 29,767 shares of the business's stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $3.97, for a total transaction of $118,174.99. Following the transaction, the director now owns 269,118 shares of the company's stock, valued at $1,068,398.46. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 60,374 shares of company stock worth $233,797 in the last three months. 3.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in MXCT. Swedbank AB acquired a new position in MaxCyte in the 1st quarter valued at about $6,704,000. Blair William & Co. IL lifted its stake in shares of MaxCyte by 7.3% in the 1st quarter. Blair William & Co. IL now owns 273,064 shares of the company's stock worth $1,144,000 after acquiring an additional 18,501 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of MaxCyte in the first quarter valued at about $174,000. US Bancorp DE increased its stake in shares of MaxCyte by 960.0% during the first quarter. US Bancorp DE now owns 95,852 shares of the company's stock worth $402,000 after acquiring an additional 86,809 shares during the period. Finally, Vanguard Group Inc. lifted its position in MaxCyte by 1.2% in the first quarter. Vanguard Group Inc. now owns 5,347,112 shares of the company's stock valued at $22,404,000 after purchasing an additional 65,004 shares during the period. 68.81% of the stock is owned by institutional investors and hedge funds.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.